Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOF 93 12-1 Month Momentum % is -15.79% as of Aug. 11, 2026. GuruFocus rates KYKOF with a GF Score™ of 93/100 and a GF Value™ of $12.29. The stock has 2 warning signs investors should review. Among 1,016 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 63.68% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-11), Kyowa Kirin Co's 12-1 Month Momentum % is -15.79%.
The industry rank for Kyowa Kirin Co's 12-1 Month Momentum % or its related term are showing as below:
KYKOF's 12-1 Month Momentum % is ranked better than 63.68% of 1016
companies
in the Drug Manufacturers industry
Industry Median: -12.73
vs KYKOF: -15.79
Kyowa Kirin Co (OTCPK:KYKOF) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Kyowa Kirin Co 12-1 Month Momentum % Related Terms
KYKOF vs ZTS: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's 12-1 Month Momentum % falls into.
Kyowa Kirin Co (OTCPK:KYKOF) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -15.79% mean?
Kyowa Kirin Co (KYKOF) has a 12-1 Month Momentum % of -15.79% as of Aug. 11, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Kyowa Kirin Co and its competitors. According to the industry distribution chart, Kyowa Kirin Co ranks #369 out of 1016 companies in the Drug Manufacturers industry, placing it in the top 36.3%.
Is Kyowa Kirin Co's 12-1 Month Momentum % too high?
Kyowa Kirin Co's current 12-1 Month Momentum % is -15.79%. Based on the distribution chart, Kyowa Kirin Co ranks #369 out of 1016 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's 12-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #369 out of 1016 companies for 12-1 Month Momentum %. This puts Kyowa Kirin Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Kyowa Kirin Co and its competitors. Kyowa Kirin Co's current 12-1 Month Momentum % is -15.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Kyowa Kirin Co (KYKOF) has a current 12-1 Month Momentum % of -15.79%. The stock's GF Value™ is $12.29, compared to a current price of $14.43 — trading 17.4% above its estimated fair value. The current 12-1 Month Momentum % is -15.79%. Kyowa Kirin Co's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current 12-1 Month Momentum % is -15.79% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be overvalued.
The current stock price of $14.43 is trading 17.4% above its estimated GF Value™ of $12.29.
Key valuation signals for KYKOF:
12-1 Month Momentum %: -15.79%
GF Value™: $12.29 vs. price of $14.43 (17.4% above fair value)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
93GF Score
Get the complete analysis for KYKOF
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
